At-home Leqembi in 2026 still requires full MRI monitoring for ARIA. ARIA means amyloid-related imaging abnormalities, swelling or bleeding in the brain linked to the drug. People with mild cognitive impairment due to Alzheimer's are in the intended early-disease group. Home injections replace infusion-center visits, not brain scans or clinician oversight.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is at-home Leqembi for?
- Why does MRI monitoring stay the same at home?
- What does ARIA feel like?
- What should you ask before the first dose?
Who is at-home Leqembi for?
Leqembi is for early disease only, mild cognitive impairment or mild dementia due to Alzheimer's. Treatment generally requires confirmed amyloid pathology, the population studied in trials.
The at-home regimen covers initiation through maintenance. As BioPharm International reports, eligible patients can start and continue by self- or caregiver-injection or switch between IV and subcutaneous routes with the initiation-dose report. The FDA approved the weekly 500-mg subcutaneous dose, given as two 250-mg injections, on July 13, 2026.
Why does MRI monitoring stay the same at home?
The FDA requires a recent baseline brain MRI before starting Leqembi. Surveillance scans follow before the 3rd, 5th, 7th and 14th infusions, with the pre-3rd scan added in 2025 to catch swelling earlier, according to the FDA safety communication. The same timetable applies for IV and subcutaneous lecanemab.
Medscape describes it in 2026 labeling as scans after about 1, 2, 3 and 6 months, with greatest vigilance in the first 14 weeks, in its home-lecanemab analysis. At-home injection does not make treatment simple to take at home. Injection training, guided first doses, scheduled MRIs and clinician oversight remain required.
What does ARIA feel like?
Leqembi carries a boxed warning for ARIA-E swelling and ARIA-H bleeding. These changes often resolve and cause no symptoms, so scans can find problems before a person feels ill.
When symptoms occur, they need prompt care. Call the care team right away for:.
- new headache, confusion, or dizziness
- vision changes or nausea
- new difficulty walking
What should you ask before the first dose?
Ask about ApoE ε4 testing and counseling. People with two ApoE ε4 copies face higher ARIA incidence, including symptomatic and severe ARIA, and the Alzheimer's Association toolkit recommends genotyping before treatment with the lecanemab toolkit. Ask how first doses, training and MRI scheduling will work.
Confirm who reviews each scan, who to call after hours, and what symptoms pause the next dose. Bring a caregiver to training when possible. Keep the MRI appointments even when injections feel routine, because most risk clusters early.
You Might Also Like
- High Cholesterol in the 2026 WHO Dementia Guideline: Questions Adults Over 65 Can Discuss With a Clinician
- CMS GUIDE Dementia Quality Measures for 2026: Eligibility and Participation Questions for Family Caregivers
- CMS GUIDE 24-Hour Dementia Support in 2026: Eligibility and Participation Questions for Family Caregivers
